Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

Pacur To Acquire CAROLEX To Expand Global Position And Customer Reach

Pacur, LLC, a market leading supplier of specialty plastic packaging materials for the medical device industry, announced today that it has signed a definitive agreement to acquire CAROLEX SAS, a polyethylene terephthalate glycol (“PETG”) sheet extruder based in France. The acquisition strengthens Pacur’s medical device focus in Europe and extrusion capabilities to meet the global demands of customers.

Pacur is the leading supplier of extruded PETG sheet used principally to provide rigid, high-performance packaging for medical devices. The company also produces sheet for certain specialty graphics, pharmaceutical packaging, and food packaging applications.

CAROLEX represents Pacur’s first acquisition and extends the company’s best-in-class customer service and reputation for quality into Europe. Oshkosh, WI-based Pacur is acquiring CAROLEX from epsotech Holding GmbH, a supplier of primarily thick gauge extruded plastic sheet with seven other factories in Europe. Pacur is a portfolio company of middle-market private equity firm Gryphon Investors, which invested in Pacur in 2020. Terms of the transaction, which is expected to close by year end, were not disclosed.

The CAROLEX management team will remain in place, led by Managing Director Sylvain Forestier.

John Carlson, CEO of Pacur said, “The past two years have certainly highlighted how important the entire medical supply chain has become, and has reinforced Pacur’s commitment to increasing our global presence. We are excited to join forces with Sylvain and the entire CAROLEX team and to develop a strong partnership in technology and customer satisfaction. We look forward to investing in Carolex and bringing Pacur’s market-leading capabilities in product innovation to Carolex’s European customers.”

Mr. Forestier commented, “We are delighted to become part of a top-notch global supplier. Under epsotech, we strengthened our production capacity and developed a world-class service capability, and we are now eager to join Pacur to support our next phase of growth. We look forward to continuing our commitment to innovation and leadership and gaining increased resources to better serve our customers.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Laverock Therapeutics Raises £13.5M

Laverock Therapeutics notes the funding will enable further development of the GEiGS technology and progression of Laverock’s programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumor responsive T-cell and macrophage-based immune therapies, through to in vitro and in vivo validation.

SpineX Receives NIH SBIR Phase II Award for SCiP Clinical Trial in Children With CP

These funds will go towards completing a pivotal clinical trial to test the efficacy and safety of our proprietary SCiP™ device in children living with Cerebral Palsy (CP) notes SpineX.

Summus Raises $19.5 Million

Fundraise supports market expansion with Summus emerging as the premier clinical platform to share and access high quality specialty expertise across the continuum of care — serving employers, payers, health systems and physician groups.

Thirona Raises €7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine

With this financing, Thirona plans to accelerate the adoption of its break-through innovations for precision medicine.

Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes

The trial will evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence, notes Levee Medical.

By using this website you agree to accept Medical Device News Magazine Privacy Policy